These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32500079)

  • 1. Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells.
    Mika T; Maghnouj A; Klein-Scory S; Ladigan-Badura S; Baraniskin A; Thomson J; Hasenkamp J; Hahn SA; Wulf G; Schroers R
    Front Mol Biosci; 2020; 7():84. PubMed ID: 32500079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients.
    Haderbache R; Warda W; Hervouet E; da Rocha MN; Trad R; Allain V; Nicod C; Thieblemeont C; Boissel N; Varlet P; Agha IY; Bouquet L; Guiot M; Venet F; Sujobert P; Roussel X; Rouzaire PO; Caillot D; Casasnovas O; Bories JC; Bachy E; Caillat-Zucman S; Deschamps M; Ferrand C
    J Transl Med; 2021 Jun; 19(1):265. PubMed ID: 34154602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel.
    Fehse B; Badbaran A; Berger C; Sonntag T; Riecken K; Geffken M; Kröger N; Ayuk FA
    Mol Ther Methods Clin Dev; 2020 Mar; 16():172-178. PubMed ID: 32055645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR.
    Badbaran A; Berger C; Riecken K; Kruchen A; Geffken M; Müller I; Kröger N; Ayuk FA; Fehse B
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32698364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of cell-free DNAfor the analysis of CD19-CAR-T cells during lymphoma treatment.
    Mika T; Thomson J; Nilius-Eliliwi V; Vangala D; Baraniskin A; Wulf G; Klein-Scory S; Schroers R
    Mol Ther Methods Clin Dev; 2021 Dec; 23():539-550. PubMed ID: 34853800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
    Schubert ML; Dietrich S; Stilgenbauer S; Schmitt A; Pavel P; Kunz A; Bondong A; Wegner M; Stadtherr P; Jung S; Ho AD; Müller-Tidow C; Schmitt M; Dreger P
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1575-1580. PubMed ID: 32422254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
    Sharma P; King GT; Shinde SS; Purev E; Jimeno A
    Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Real-Time Quantitative PCR Targeting the Viral Vector for the Monitoring of Patients Treated with Axicabtagene Ciloleucel.
    Baras A; Bocket L; Beauvais D; Hallaert C; Varlet P; Yakoub-Agha I; Hober D; Alidjinou EK
    J Mol Diagn; 2021 Apr; 23(4):447-454. PubMed ID: 33385585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
    Sesques P; Ferrant E; Safar V; Wallet F; Tordo J; Dhomps A; Karlin L; Brisou G; Vercasson M; Hospital-Gustem C; Schwiertz V; Ranchon F; Rioufol C; Choquet M; Sujobert P; Ghergus D; Bouafia F; Golfier C; Lequeu H; Lazareth A; Novelli S; Devic P; Traverse Glehen A; Viel S; Venet F; Mialou V; Hequet O; Chauchet A; Arkam Y; Nicolas-Virelizier E; Peyrade F; Cavalieri D; Ader F; Ghesquières H; Salles G; Bachy E
    Am J Hematol; 2020 Nov; 95(11):1324-1333. PubMed ID: 32744738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma.
    Jain MD; Bachmeier CA; Phuoc VH; Chavez JC
    Ther Clin Risk Manag; 2018; 14():1007-1017. PubMed ID: 29910620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring anti-CD19 chimeric antigen receptor T cell population by flow cytometry and its consistency with digital droplet polymerase chain reaction.
    Cheng J; Mao X; Chen C; Long X; Chen L; Zhou J; Zhu L
    Cytometry A; 2023 Jan; 103(1):16-26. PubMed ID: 35875964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unlocking Predictive Power: Quantitative Assessment of CAR-T Expansion with Digital Droplet Polymerase Chain Reaction (ddPCR).
    Galli E; Viscovo M; Fosso F; Pansini I; Di Cesare G; Iacovelli C; Maiolo E; Sorà F; Hohaus S; Sica S; Bellesi S; Chiusolo P
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of single copy gene‑based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19‑directed CAR T cells in treated patients.
    Schubert ML; Berger C; Kunz A; Schmitt A; Badbaran A; Neuber B; Zeschke S; Wang L; Riecken K; Hückelhoven-Krauss A; Müller I; Müller-Tidow C; Dreger P; Kröger N; Ayuk FA; Schmitt M; Fehse B
    Int J Oncol; 2022 May; 60(5):. PubMed ID: 35294040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma.
    Oluwole OO; Jansen JP; Lin VW; Chan K; Keeping S; Navale L; Locke FL
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1581-1588. PubMed ID: 32561336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR.
    Schubert ML; Kunz A; Schmitt A; Neuber B; Wang L; Hückelhoven-Krauss A; Langner S; Michels B; Wick A; Daniel V; Müller-Tidow C; Dreger P; Schmitt M
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33007926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
    Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
    Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
    [No Abstract]   [Full Text] [Related]  

  • 17. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
    Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
    Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
    Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS
    Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma.
    Kato K; Makita S; Goto H; Kanda J; Fujii N; Shimada K; Akashi K; Izutsu K; Teshima T; Fukuda N; Sumitani T; Sumi H; Shimizu S; Kakurai Y; Yoshikawa K; Tobinai K; Usui N; Hatake K
    Int J Clin Oncol; 2022 Jan; 27(1):213-223. PubMed ID: 34599413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Safety and efficacy of CD19-targeted CAR-T cells in 14 patients with refractory/relapsed Philadelphia chromosome-positive acute B-precursor lymphoblastic leukemia].
    He CX; Xue L; Qiang P; Xu H; Zhang XH; Liu X; Zhu WW; Cai XY; Liu HL; Sun ZM; Wang XB
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):490-494. PubMed ID: 32654463
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.